Diş Hekimliğinde Botulinum Toksininin Tedavi Amaçlı Uygulamaları

Öz

Botulinum toksini Clostridium botulinum bakterisi tarafından üretilen bir nörotoksin olup nöromüsküler kavşakta felce yol açarak etki eder. Botulinum toksini uzun yıllardır terapötik amaçlı olarak şaşılık ve blefarospazm tedavisinde kullanılmaktadır. O zamandan bu yana botulinum toksininin etkinlikleri ve serötipleri araştırılmaktadır. Botoks enjeksiyonu minimal invaziv bir prosedür olup diş hekimliğinde temporomandibular eklem disfonksiyonları, bruksizm, masseter hipertrofisi, dişeti gülümsemesi ve trigeminal nevralji tedavilerinde kullanılmaktadır. Bu derleme çalışmasında botoksun diş hekimliğinde kullanımının incelenmesi amaçlanmıştır.

Anahtar Kelimeler

• Botulinum toksini
• botoks
• diş hekimliği
• dişeti gülümsemesi.

Clinical Therapeutic Applications of Botulinum Toxin in Dentistry

Öz

Botulinum toxin is a neurotoxin, which is produced by Clostridium botulinum and acts by causing paralysis at the neuromuscular junction. Botulinum toxin has been used for therapeutic purposes for many years in the treatment of strabismus and blepharospasm. Since then, the efficacy and serotypes of botulinum toxin have been investigated. Botox injection is a minimally invasive procedure and is used in dentistry for the treatment of temporomandibular joint disorders, bruxism, masseteric hypertrophy, gummy smile and trigeminal neuralgia. This review article emphysis on the investigation of botox in dentistry.

Anahtar Kelimeler

• Botulinum toxin
• botox
• dentistry
• gummy smile.

Kaynakça

1. Referans1. Jain M, Bansal A, Agarwal D, Joshi M. Botox in dentistry: The healing side of A poison. J Adv Med Dent Scie 2014;2(1):95–9. Referans2. Sheen D, Clarkson E. Botox and Dermal Fillers: Review and Its Role in the Dental Office. Dent Clin North Am 2020;64(2):325-339.
2. Referans3. Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Current Opinion in Pharmacology 2005;5(3):274–79.
3. Referans4. Barbano R. Risks of erasing wrinkles: Buyer beware!. Neurology 2006;67(10):E17–18.
4. Referans5. Nayyar P, Kumar P, Nayyar PV, Singh A. BOTOX: Broadening the Horizon of Dentistry. J Clin Diagn Res 2014;8(12):ZE25-9.
5. Referans6. Nestor MS, Ablon GR. Duration of action of abobotulinumtoxinA and onabotulinumtoxinA: a randomized, double-blind study using a contralateral frontalis model. J Clin Aesthet Dermatol 2011;4(9):43–9.
6. Referans7. Srivastava S, Kharbanda S, Pal US, Shah V. Applications of botulinum toxin in dentistry: A comprehensive review. Natl J Maxillofac Surg 2015;6(2):152. Referans8. Azam A, Manchanda S, Thotapalli S, Kotha SB. Botox therapy in dentistry: A Review. J Int oral Heal JIOH 2015;7(Suppl 2):103.
7. Referans9. Patel D, Mehta F, Trivedi R, Thakkar S, Suthar J. Botulinum toxin and gummy smile-a review. IOSR J Dent Med Sci 2013;4(1):2279–861. Referans10. van Ermengem E. Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus. Zeitschr f Hygiene 1897;26:1–56. Referans11. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973;12(12):924-927.
8. Referans12. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm (Vienna) 2008;115(4):559-65. Referans13. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulism toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059-70.

9. Referans14. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2014 Jan 15;209(2):183-91.
10. Referans15. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(Suppl 1):S9–15.
11. Referans16. Horowitz BZ. Botulinum toxin. Crit Care Clin 2005;21(4):825–39.
12. Referans17. Edwards M. Anal fissure. Dumas Ltd Retrieved August 2006;21:2010.
13. Referans18. Scaglione F. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel) 2016;8(3):65.
14. Referans19. Niamtu J. Cosmetic facial surgery. 2nd edition. Edinburgh (Scotland): Elsevier; 2018. Referans20. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56(1):80–99.
15. Referans21. Hexsel DM, de Almeida AT, Rutowitsch M, de Castro IA, Silveira VLB, Gobatto DO, et al. Multicenter, Double-Blind Study of the Efficacy of Injections With Botulinum Toxin Type A Reconstituted Up to Six Consecutive Weeks Before Application. Dermatol Surg 2003 May;29(5):523-9;discussion529.
16. Referans22. Park MY, Ahn KY. Effect of the refrigerator storage time on the potency of botox for human extensor digitorum brevis muscle paralysis. J Clin Neurol 2013;9(3):157-64.
17. Referans23. Singh S, Singla L, Anand T. Esthetic Considerations in Orthodontics: An Overview. Dent J Adv Stud 2021;9:55–60.
18. Referans24. Ricketts RM. Facial art, the divine proportion and the science of esthetics. In: Ricketts RM ed Provocations and Perceptions in Craniofacial Orthopedics, Vol 1 Boulder, CO: RMO 1989:149–202.
19. Referans25. Polo M. Botulinum toxin type A in the treatment of excessive gingival display. Am J Orthod Dentofacial Orthop. 2005;127(2):214-18.
20. Referans26. Garber DA, Salama MA. The aesthetic smile: Diagnosis and treatment. Periodontol 2000 1996;11:18-28.
21. Referans27. Hwang WS, Hur MS, Hu KS, Song WC, Koh KS, Baik HS, et al. Surface anatomy of the lip elevator muscles for the treatment of gummy smile using botulinum toxin. Angle Orthod 2009;79(1):70-77.
22. Referans28. Norton NS. Netter’s head and neck anatomy for dentistry. 2nd edition. Philadelphia: Elsevier; 2012.
23. Referans29. Bentsianov BL, Francis A, Blitzer A. Botulinum toxin treatment of temporomandibular disorders, masseteric hypertrophy, and cosmetic masseter reduction. Operative Techniques in Otolaryngology-Head and Neck Surgery 2004;15(2):110-13.
24. Referans30. Olivo SA, Bravo J, Magee DJ, Thie NM, Major PW, Flores-Mir C. The association between head and cervical posture and temporomandibular disorders: A systematic review. J Orofac Pain 2006;20(1):9-23.
25. Referans31. Okeson JP. Orofacial Pain: Guidelines for Assessment, Diagnosis and Management. Chicago: Quintessence Co. 1996:45–52.
26. Referans32. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6(4):301-55.
27. Referans33. Castenada R. Occlusion. In: Kaplan A, Assael L (eds). Temporomandibular Disorders. Philadelphia, Pa: Saunders, 1992.
28. Referans34. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain 2002;18(6 Suppl):S198-203.
29. Referans35. Schwartz M, Freund B. Botulinum Toxin A Therapy for Temporomandibular Disorders. Philadelphia, Pa: Lippincott Williams & Wilkins, 2002.
30. Referans36. Lovely FW, Copeland RA. Reduction eminoplasty for chronic recurrent luxation of the temporomandibular joint. J Can Dent Assoc 1981;3:179-184.
31. Referans37. Moore AP, Wood CG. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A. Br Dent J 1997: 183: 415–417.
32. Referans38. Kwon KH, Shin KS, Yeon SH, Kwon DG. Application of botulinum toxin in maxillofacial field: part I. Bruxism and square jaw. Maxillofac Plast Reconstr Surg. 2019;41(1):38.
33. Referans39. Glaros A, Tabacchi K, Glass EG. Effect of parafunctional clenching on TMD pain and hearing loss. J Orofacial Pain. 1998;12(2):145-52.
34. Referans40. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989;98(2):93-97.
35. Referans41. Laskawi R, Rohrbach S. Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin. Laryngorhinootologie. 2001;80(12):708- 13.
36. Referans42. Alshadwi A, Nadershah M, Osborn T. Therapeutic applications of botulinum neurotoxins in head and neck disorders. Saudi Dent J. 2015;27:3-11.
37. Referans43. Boyle JO, Reid V. Complications of Surgery of the Oral Cavity. In: Complications in Head and Neck Surgery. Elsevier; 2009. p. 257–66.
38. Referans44. Laskawi R, Drobik C, Schönebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey’s syndrome). Laryngoscope. 1998;108(3):381-84.
39. Referans45. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
40. Referans46. Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014 Sep 27;15(1):65.
41. Referans47. Rubis A, Juodzbalys G. The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review. J Oral Maxillofac Res. 2020;11(2):e2.